Phenotypes Associated with This Genotype

Genotype
MGI:4455054

• Allelic Composition: Nr3c1^tm3Gsc/Nr3c1^tm3Gsc
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

skeleton

skeleton phenotype ( J:160669 )

N • bone formation with prednisolone treatment for 2 weeks is repressed in controls and mutants; bone mass and trabecular thickness as well as strong reduction in osteoblast and osteocyte numbers and osteoblast surface area are observed in controls and experimental animals with inhibition of bone formation by prednisolone

N • dexamethasone-induced apoptosis is observed in cultured mutant and wild-type cells

N • in dexamethasone-treated cultures, postconfluential cell numbers are slightly decreased, similar to wild-type cultures

N • alkaline phosphatase activity and matrix mineralization are inhibited by dexamethasone treatment in mutant and wild-type cultures

N • basal osteoclastogenesis is not affected in mutant cell culture; dexamethasone suppresses osteoclastogenesis similary in mutant and wild-type cultures

abnormal osteoblast physiology ( J:160669 )

• proliferation of preconfluent preosteoblasts from neonatal calvaria is lower in culture compared to wild-type cells

• treatment with dexamethasone does not affect mutant cells but completely inhibits osteoblast proliferation in cultures of wild-type cells

cellular

abnormal osteoblast physiology ( J:160669 )

• proliferation of preconfluent preosteoblasts from neonatal calvaria is lower in culture compared to wild-type cells

• treatment with dexamethasone does not affect mutant cells but completely inhibits osteoblast proliferation in cultures of wild-type cells